Drug recall · December 16, 2020
Docetaxel Injection USP 160 mg/8mL recall
Why: CGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.
- Lots / codes
Lot #: 7S10185A, Exp. 10/31/2021
- Quantity
- 2008 vials
- Company
- Shilpa Medicare Limited, Polepally, Jadcherla, N/A
- Distribution
- Nationwide in the U.S.
- Initiated
- December 8, 2020 · Voluntary: Firm initiated
- Classified
- December 9, 2020
- Reported
- December 16, 2020
- Ended
- March 11, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Docetaxel
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.